Kerins Patrick J's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 3, 2022
- Accession no.
- 0001209191-22-000354
- Filed
- Jan 3, 2022, 8:15 PM ET
- Trade date
- Dec 30, 2021-Jan 3, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $266.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kerins Patrick JCIK 0001235112 | 10% Owner |
| Sandell Scott DCIK 0001237289 | 10% Owner |
| Baskett ForestCIK 0001277631 | 10% Owner |
| New Enterprise Associates 14, L.P.CIK 0001544328 | 10% Owner |
| NEA Partners 14, L.P.CIK 0001551531 | 10% Owner |
| Nea 14 GP, LtdCIK 0001551532 | 10% Owner |
| Sonsini Peter W.CIK 0001559807 | 10% Owner |
| Florence Anthony A. Jr.CIK 0001559827 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2021 | Common Stock | SSaleDisposed | −21,858 | $2.29 | −$50,065.75 | 3,633,558 | Direct | |
| Dec 31, 2021 | Common Stock | SSaleDisposed | −49,953 | $2.25F2 | −$112,409.24 | 3,583,605 | Direct | |
| Jan 3, 2022 | Common Stock | SSaleDisposed | −44,665 | $2.34 | −$104,395.5 | 3,538,940 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.